From Medscape Oncology

Medscape Coverage from the

European Lung Cancer Conference (ELCC) 2017

May 05 - 08, 2017; Geneva, Switzerland

May 05 - 08, 2017 Geneva, Switzerland

ELCC G-CSF Use in Small Cell Lung Cancer: New Data 'Comforting' Although patients with SCLC given granulocyte colony-stimulating factors during chemo-radiotherapy had an increased risk for hematologic complications, the drugs can be used safely, say researchers.
Medscape Medical News, May 9, 2017
ELCC Questions Over 'Flu Jab' in Lung Cancer Patients on PD Inhibitors Patients with cancer receiving immune checkpoint inhibitors could be at increased risk for adverse events compared with the general population if they are given a yearly flu jab, say Swiss researchers.
Medscape Medical News, May 8, 2017
ELCC PD-Inhibitor Benefits 'Continue Beyond Progression' in NSCLC Non-small cell lung cancer patients can benefit from immunotherapy even after progression, from both drug continuance and the ongoing effect of prior treatment on salvage therapy, reveal two studies.
Medscape Medical News, May 8, 2017

Conference News

ELCC White Blood Cells May Point to Checkpoint Inhibitor Response
Medscape Medical News, May 12, 2017
ELCC Endocrine Alterations in Many Patients on PD Inhibitors
Medscape Medical News, May 12, 2017
ELCC G-CSF Use in Small Cell Lung Cancer: New Data 'Comforting'
Medscape Medical News, May 9, 2017

ELCC Questions Over 'Flu Jab' in Lung Cancer Patients on PD Inhibitors
Medscape Medical News, May 8, 2017
ELCC PD-Inhibitor Benefits 'Continue Beyond Progression' in NSCLC
Medscape Medical News, May 8, 2017
ELCC Do Women Need Lung Cancer Screening Less Often Than Men?
Medscape Medical News, May 8, 2017

Most Popular News from the Last ELCC

Immunotherapies for NSCLC 'Perform Well in Real World' The anti-PD-1 agents nivolumab and pembrolizumab achieve real-world outcomes comparable to that seen in trials, although survival is closely linked to patient performance status.
Medscape Medical News, Apr 18, 2016
Osimertinib Activity When Used Up Front in EGFR+ NSCLC The third-generation EGFR inhibitor osimertinib extends survival when used as a first- and second-line therapy in non-small cell lung cancer.
Medscape Medical News, Apr 15, 2016
Doubts Over PD Inhibitor Plus TKI Combo in NSCLC Combining checkpoint inhibitors with tyrosine kinase inhibitors in non-small cell lung cancer adds little benefit but substantially increases serious adverse events.
Medscape Medical News, Apr 21, 2016

Medscape Oncology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

ELCC on Twitter

Previous Coverage

Related Resource

Lung Cancer News & Perspectives

All material on this website is protected by copyright, Copyright © 1994-2018 by WebMD LLC. This website also contains material copyrighted by 3rd parties.